A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Mild Cognitive Impairment Clinical Trial

Official title:

A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02240459
• Other study ID #: FES-COG 1808
• Status: Completed
• Phase: Phase 2
• Start date: August 2016
• Est. completion date: January 31, 2020

Study information

• Verified date: February 2020
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Description:

This is a randomized placebo controlled, blinded four way cross over trial of the effect of medications used to treat overactive bladder on the cognition of older men and women with mild cognitive impairment. Each treatment phase is a week, with a weeks washout period before starting the next treatment. Cognitive testing is by way of a validated computer assisted battery of tests

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: January 31, 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

1. The subject is either male or female and = 75 years of age.

2. The subject has OAB as determined by ICS criteria

3. The subject has mild cognitive impairment as determined by NIA criteria

4. The subject is competent to give informed consent and perform the tasks associated with the study

5. The subject has a body mass index (BMI) between 18.0 to 30.0 kg/m2 inclusive.

6. Written informed consent has been obtained.

7. The subject is available to complete the study.

8. At training visits (visit 2): the subject has performed at or above the minimum level on at least one occasion for each individual task measure in cognitive function test training.

Exclusion Criteria:

1. The subject does not have OAB.

2. The subject has either dementia or moderate to severe cognitive impairment at screening.

3. The subject has probable clinical depression as determined by Geriatric Depression Scale (GDS) short form >5 at screening.

4. Subjects taking any cognitive enhancers (cholinesterase inhibitors or memantine).

5. The subject has a history of allergy to the study drug(s), to any component of the dosage form or any other allergy, which, in the opinion of the Investigator, contraindicates their participation.

6. The subject has any clinically significant abnormal heart rate or blood pressure measurements, at the screening visit, which, in the opinion of the Investigator, prevent safe participation in the study. (dBP< 60mmHg or > 90mmHg, sBP < 95mmHg or > 160mmHg or HR < 40bpm or > 100bpm).

7. Subjects with known history of urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony) or severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, uncontrolled narrow angle glaucoma or shallow interior chamber or subjects deemed to be at risk for these conditions.

8. Subjects undergoing haemodialysis or who have severe renal impairment.

9. Subjects with severe hepatic impairment, defined as Child-Pugh grade IV.

10. Subjects taking potent CYP 3A4 inhibitors which would, under normal circumstances, require adjustment of the dose of the test drugs.

11. Subject has taken prescribed medication within 14 days prior to the first study day or over-the-counter medicine (including vitamins and herbal remedies) within 48 hours prior to the first study day, which in the opinion of the Investigator, will interfere with the study procedures or compromise safety.

12. Subject has an average weekly alcohol intake of greater than 21 units (male) or 14 units (female) within the 90 days prior to the study. 1 unit is 270cc of beer, 40cc of spirits or 125cc of wine.

13. History of smoking more than 10 cigarettes (or the equivalent amount of tobacco) per day within the 90 days prior to the study.

14. Subject has participated in any clinical study within the last 90 days.

15. Any clinically significant abnormality following Investigator review of the pre study physical examination.

16. Any clinical condition, which, in the opinion of the Investigator, would not allow safe completion of the study.

17. Any subjects who, in the opinion of the investigator, may find it difficult to adhere to the provisions of treatment and observation specified in the protocol.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment
• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Drug:
• fesoterodine 4mg
7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
• Oxybutynin
5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
• placebo
placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
• fesoterodine 8mg
2, 4mg fesoterodine capsules taken together in the morning

Locations

Country	Name	City	State
Canada	Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp	Edmonton	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
University of Alberta	Pfizer

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013 Jul;64(1):74-81. doi: 10.1016/j.eururo.2013.01.002. Epub 2013 Jan 11. — View Citation

Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009 Nov;8(6):615-26. doi: 10.1517/14740330903260790. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	continuity of attention	Continuity of Attention: Accuracy of responding in Choice Reaction Time task Percent Target Detection in Digit Vigilance task False Alarms in Digit Vigilance task	1 and 4h post dose
Secondary	cognitive function	includes the following domains of cognition; power of attention,; quality of working memory,; quality of episodic secondary memory,; speed of memory; Montreal Cognitive assessment score	1 and 4h post last dose of study drug